GlassScriptPhysician profile
Richard A Le
NPI 1962421016
$16,490.41
in general payments reported to CMS, 2019-2025
50 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,526 · 2020: $1,643 · 2021: $2,441 · 2022: $2,710 · 2023: $2,327 · 2024: $2,856 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,021 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,021.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,362.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $2,134.38 | 2019-2025 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $1,250.91 | 2019-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $1,193.81 | 2019-2025 | Vemlidy, Livdelzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,158.83 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $975.67 | 2019-2022 | |
| Astellas Pharma US INC | $939.14 | 2019-2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $918.64 | 2022-2025 | |
| Glaxosmithkline, LLC. | $827.06 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $750.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $570.92 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $404.35 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $327.46 | 2019-2025 | |
| Abbott Laboratories | $279.25 | 2021-2025 | Eterna, Freestyle Libre 3 |
| Radius Health, INC. | $230.48 | 2019-2025 | Tymlos |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.